ArticleLeukemia2017
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.
Abstract read
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 64 citations in OpenAlex.
- A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.Haematologica · 2022Trial
- Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.Cytotherapy · 2020Trial
- Targeting TGFBR1 with the Investigational Inhibitor TP-6379 Improves Hematopoiesis in Low-Risk MDS Ex Vivo.Cells · 2026Article
- Mendelian randomization analysis of immune cell populations, serum metabolites and hepatocellular carcinoma risk.Discover oncology · 2025Article
- Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.Biomolecules · 2025Review
- A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.Cancer biology & therapy · 2024Review
- Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.Annals of hematology · 2024Review
- Review
- First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.Clinical and translational science · 2024Article
- Exploiting innate immunity for cancer immunotherapy.Molecular cancer · 2023Review
- Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.Biomarker research · 2023Review
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147/EMMPRIN for monocyte activation by the DAMP S100A8/S100A9.Frontiers in immunology · 2023Article
- New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology.Journal of clinical medicine · 2022Review
- Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.Journal of clinical medicine · 2022Review
- Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.Diagnostics (Basel, Switzerland) · 2022Review
- Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.Journal of hematology & oncology · 2022Review
- Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS).Current problems in cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
E A EksiogluImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
X ChenImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
K-H HeiderBoehringer Ingelheim RCV, Vienna, Austria.
B RueterBoehringer Ingelheim Pharma GmbH &Co. KG, Biberach/Riss, Germany.
K L McGrawDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
A A BasiorkaDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and the Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL, USA.
M WeiImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
A BurnetteImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
P ChengImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
J LancetImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
R KomrokjiImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
J DjeuImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
A ListImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
S WeiImmunology Program and Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Moffitt Cancer Center · USBoehringer Ingelheim (Austria) · ATBoehringer Ingelheim (Germany) · DE
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MModulation of the S100A9/CD33 Pathway by the Flavonoids ICA and ICT on the TumorK01CA187020 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EKSIOGLU, ERIKA ADRIANA · 2014 to 2018
$456kNCI NIH HHS K01 CA187020NCI NIH HHS P30 CA076292
Abstract
We recently reported that the accumulation of myeloid-derived suppressor cells (MDSC), defined as CD33
Indexed as
Molecular Targeted TherapyAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityBone MarrowFemaleGenetic EngineeringGenomic InstabilityHematopoiesisHumansImmunoglobulin Fc FragmentsMaleMiddle AgedMyelodysplastic SyndromesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBI 836858CD33 protein, humanImmunoglobulin Fc FragmentsReactive Oxygen SpeciesSialic Acid Binding Ig-like Lectin 3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.